Investigation of pharmacokinetics, safety, and tolerability of multiple oral and subcutaneous doses of NNC0519-0130 in Japanese and non-Japanese male participants

Tsukasaki Nobuaki0 个研究点目标入组 70 人开始时间: 2023年5月26日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•Body mass index (BMI) between 23.0 kg/m2 and 39.9 kg/m2 (both inclusive) at screening with a minimum weight of 50 kg. Overweight should be due to excess adipose tissue, as judged by the investigator.
•- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

•- Any disorder, which in the investigator opinion might jeopardise safety of participant or compliance with the protocol.
•- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, GI, or endocrinological conditions.
•- HbA1c >= 6.5 % (48 mmol/mol) at screening.
•-Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid (ASA), and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening.

发起方

Tsukasaki Nobuaki